Notícias · Recifes

New approach to gene correction for iron storage disease

Hereditary primary hemochromatosis is caused by a single faulty building block in a gene. This leads to iron overload, which can have serious consequences for organs and joints. In preclinical studies, researchers have already successfully treated this genetic defect using a targ

Admin Recifes 15/07/2026 2

New clinical data advances stem cell-based cell therapy for Parkinson's disease

New clinical data from the STEM-PD Phase I/II clinical trial have been presented at the ISSCR 2026 Annual Meeting. The study reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells for the

Admin Recifes 15/07/2026 2

Long-term stroke data reveal stem cell therapy's safety, biological activity over years

Previously unpublished long-term clinical and imaging findings from participants treated with an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy for chronic ischemic stroke were presented at the ISSCR 2026 Annual Meeting.

Admin Recifes 15/07/2026 2

New data highlight off-the-shelf iPSC-derived CAR T-cell therapy for treatment-resistant s

New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell therapy for patients with treatment-resistant systemic sclerosis, a rare autoimmune disease with high mortality.

Admin Recifes 15/07/2026 2

Data highlight progress toward personalized stem cell therapy for Parkinson's disease

Interim clinical findings from the first Phase I/IIa trial using autologous-induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor cells, along with the novel quality-control tools developed to manufacture these individualized therapies, have been presented by Jea

Admin Recifes 15/07/2026 2

Huntington's treatment quest reaches first pluripotent stem cell trial, with safety now un

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented at the ISSCR 2026 Annual Meeting. The Phase Ib/IIa REGEN4HD study represents a significant translational milestone following years of p

Admin Recifes 15/07/2026 2

Data demonstrate 1-year survival of stem cell-derived neural progenitor cells in patients

New, previously unpublished clinical data have been presented at ISSCR 2026 demonstrating that transplanted human neural progenitor cells survived for at least one year following subretinal transplantation in patients with retinitis pigmentosa (RP), while maintaining a favorable

Admin Recifes 15/07/2026 2

GLP-1 agonists may help people with diabetes and long COVID, study in mice suggests

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published in the Journal of Virology, suggest that the drugs may offer benefits to another patient popula

Admin Recifes 15/07/2026 3

Genetic study links IBS to lipid metabolism and triglyceride regulation

Irritable bowel syndrome (IBS) is a common condition that affects more than 10% of the general population, causing recurrent abdominal pain, bloating, constipation and diarrhea. IBS is considered a disorder of gut-brain interaction, and previous research, including genetic resear

Admin Recifes 15/07/2026 2

Cyclospora parasite is running rampant in Michigan. Will it spread elsewhere?

If you're anywhere near Michigan, you might want to skip the cilantro—or at least wash it really well. According to the U.S. Centers for Disease Control and Prevention, there's a parasite known as Cyclospora on the loose. It's tiny, it spreads quickly, and it's making hundreds of

Admin Recifes 15/07/2026 3

Researchers uncover hormone link between gut and brain in anorexia nervosa

People with anorexia nervosa have unusually high levels of a hormone called LEAP2 in their blood when they are in the acute phase of the disorder, according to research presented at the Federation of European Neuroscience Societies (FENS) Forum 2026. Patients with the highest lev

Admin Recifes 15/07/2026 2

FDA expands use of first sickle cell disease gene therapy for children as young as 2 years

The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients ages 2 and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT). Supplement

Admin Recifes 15/07/2026 2

Acompanhe as Notícias da Recifes